The National Institute of Allergy and Infectious Diseases (NIAID) will be soliciting proposals under a new Omnibus Broad Agency Announcement (BAA) expected to be formally released on February 21, 2017.
The BAA supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases.
The research areas anticipated to be in the NIAID Omnibus BAA include:
- Adjuvant Development Program: Advancing novel adjuvants towards licensure for human use through immunological characterization studies and lead compound optimization
- Radiation/Nuclear Medical Countermeasures: New approaches to mitigate and/or treat tissue injuries arising from exposure to ionizing radiation
- Radiation/Nuclear Predictive Biomarkers and Biodosimetric Devices: Biodosimetry biomarkers and/or automated high-throughput diagnostic systems to rapidly assess levels and types of radiation exposure using minimally invasive biosamples
- Broad-spectrum Therapeutic Products for Biodefense, Anti-Microbial Resistant Infections and Emerging Infectious Diseases: Development of broad-spectrum therapeutic products for use in post-event settings following the intentional release of a NIAID Category A, B, or C Priority Pathogen, Zika virus, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens.
- Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases: Development of vaccines for use in post-event settings following the intentional release of a NIAID Category A, B, or C Priority Pathogen, Zika virus, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens.
Further details are available via Solicitation Number: HHS-NIH-NIAID-BAA2017-1.
